<DOC>
	<DOCNO>NCT02560558</DOCNO>
	<brief_summary>The purpose study transition patient stable Belatacept one year kidney transplant standard 4-week investigational 8-week belatacept dose schedule . The investigator hypothesize renal function acute rejection rate non-inferior 8-week belatacept dosing .</brief_summary>
	<brief_title>Bela 8 Week Dosing</brief_title>
	<detailed_description>The current dosing protocol patient undergone kidney transplant require Belacept give infusion every 4 week . The investigator want assess patient stable one year transplant safely transition 8-week Belatacept infusion schedule . Renal function episode acute rejection closely monitor .</detailed_description>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Adult ( age ≥18 year currently ) , Firsttime renal transplant recipient either live donor decease donor , 1. initiate belatacept time transplant 2. least one year posttransplant CNI therapy least 6 month . Patients low immunologic risk , define 1. patient first transplant PRA &lt; 50 class I class II antigens , 2. DSA ( donorspecific antibody ) , 3. one episode rejection , 4. episode rejection within last 6 month prior enrollment , 5. rejection grade IIB . Not first renal transplant , multiorgan transplant recipient History great one episode biopsyproven acute rejection , rejection Banff 97 grade IIB great , rejection within last 6 month . Pregnancy ( woman childbearing potential must use adequate contraception study ) Unwilling receive belatacept infusion Emory Transplant Center Calculated Glomerular Filtration Rate ( GFR ) less 35 . Serum creatinine enrollment 30 % high 3 month ( ±4 week ) prior randomization HbA1C great 8 enrollment Recent history significant proteinuria ( protein/Cr ratio &gt; 1 ) Nonstandard belatacept dose ( e.g . dose 5 mg belatacept/kg body weight ) Cellcept dose less 500 mg po bid . Prednisone dose great 5mg po qd within 3 month randomization Patients currently take prednisone Active infection , antibiotic antiviral drug therapy within 1 month randomization Evidence Cytomegalovirus ( CMV ) viremia clinical CMV infection within last 3 month . Polyomavirus BK PCR ( polymerase chain reaction ) load great 4.3 ( copy number great 20,0000 ) within 3 month randomization Known hepatitis B surface antigenpositive PCRpositive hepatitis B ( test require ) Known HIV ( human immunodeficiency virus infection ) ( test require ) Presence donor specific antibody Luminex single antigen assessment , panel reactivity ( PRA ) 50 % . History substance abuse psychiatric disorder compatible study adherence follow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>Transplantation Immunology</keyword>
</DOC>